Literature DB >> 15289446

Identification of the pregnancy hormone relaxin as glucocorticoid receptor agonist.

Thomas Dschietzig1, Cornelia Bartsch, Verena Stangl, Gert Baumann, Karl Stangl.   

Abstract

The insulin-like peptide relaxin is a central hormone of pregnancy, but it also produces anti-fibrotic, myocardial, renal, central-nervous, and vascular effects. Recently, two G protein-coupled receptors, LGR7 and LGR8, have been identified as relaxin receptors. Prompted by reports on immunoregulatory effects of relaxin, we investigated possible interactions with the human glucocorticoid receptor (GR). Relaxin blunted the endotoxin-induced production of inflammatory cytokines (IL-1, IL-6, TNF-alpha) by human macrophages--an effect that was suppressed by the GR antagonist RU-486. In three different cell lines, relaxin induced GR activation, nuclear translocation, and DNA binding as assessed in GRE-luciferase assays. Co-immunoprecipitation experiments revealed physical interaction of endogenous and exogenous relaxin with cytoplasmic and nuclear GR. Relaxin competed with GR agonists for GR binding, both in vivo in whole-cell assays, and in vitro in fluorescence polarization assays. Relaxin was shown to up-regulate GR protein expression as well as the number of functionally active GR sites. In LGR7/8-free cells, the relaxin-mediated activation of GR was preserved. In conclusion, relaxin acts as GR agonist--a pathway pivotal to its effects on cytokine secretion by human macrophages. These findings may deepen our understanding of relaxin's abundant physiological actions, as well as our insights into general principles of hormone signaling.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15289446     DOI: 10.1096/fj.03-1120fje

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  19 in total

Review 1.  Relaxin family peptide receptors--former orphans reunite with their parent ligands to activate multiple signalling pathways.

Authors:  M L Halls; E T van der Westhuizen; R A D Bathgate; R J Summers
Journal:  Br J Pharmacol       Date:  2007-02-12       Impact factor: 8.739

Review 2.  Cardiovascular effects of relaxin: from basic science to clinical therapy.

Authors:  Xiao-Jun Du; Ross A D Bathgate; Chrishan S Samuel; Anthony M Dart; Roger J Summers
Journal:  Nat Rev Cardiol       Date:  2009-11-24       Impact factor: 32.419

3.  Relaxin modulates proinflammatory cytokine secretion from human decidual macrophages.

Authors:  J S Horton; S Y Yamamoto; G D Bryant-Greenwood
Journal:  Biol Reprod       Date:  2011-07-06       Impact factor: 4.285

Review 4.  Relaxin in liver transplantation: A personal perspective.

Authors:  Shoichi Kageyama; Kojiro Nakamura; Jerzy W Kupiec-Weglinski
Journal:  Mol Cell Endocrinol       Date:  2019-03-03       Impact factor: 4.102

Review 5.  Novel vasodilators in heart failure.

Authors:  Payman Zamani; Barry H Greenberg
Journal:  Curr Heart Fail Rep       Date:  2013-03

Review 6.  The actions of relaxin on the human cardiovascular system.

Authors:  Mohsin Sarwar; Xiao-Jun Du; Thomas B Dschietzig; Roger J Summers
Journal:  Br J Pharmacol       Date:  2016-07-11       Impact factor: 8.739

Review 7.  International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1-4, the receptors for relaxin family peptides.

Authors:  Michelle L Halls; Ross A D Bathgate; Steve W Sutton; Thomas B Dschietzig; Roger J Summers
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

Review 8.  Relaxin: review of biology and potential role in treating heart failure.

Authors:  Sam L Teichman; Elaine Unemori; John R Teerlink; Gad Cotter; Marco Metra
Journal:  Curr Heart Fail Rep       Date:  2010-06

9.  Sub-picomolar relaxin signalling by a pre-assembled RXFP1, AKAP79, AC2, beta-arrestin 2, PDE4D3 complex.

Authors:  Michelle L Halls; Dermot M F Cooper
Journal:  EMBO J       Date:  2010-07-27       Impact factor: 11.598

10.  Combining an epithelial repair factor and anti-fibrotic with a corticosteroid offers optimal treatment for allergic airways disease.

Authors:  K P Patel; A S Giraud; C S Samuel; S G Royce
Journal:  Br J Pharmacol       Date:  2016-05-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.